Partnering

Novartis, Amgen, and the Banner Alzheimer’s Institute (BAI) have expanded their collaboration in Alzheimer’s disease to initiate a new clinical trial, the Alzheimer’s Prevention Initiative Generation Study 2. Since 2015, Amgen and Novartis have…

Merck KGaA and the Lupus Foundation of America, a national voluntary health organization based in Washington, D.C., have agreed to collaborate on The ALPHA Project: Addressing Lupus Pillars for Health…

Boehringer Ingelheim and Dicerna Pharmaceuticals, a Watertown, Massachusetts-headquartered biotechnology company, have signed a research collaboration and license agreement to discover and develop GalXC RNAi therapeutics for treating chronic liver diseases.…

AstraZeneca and MedImmune, its global biologics research and development arm, have expanded their immuno-oncology clinical collaboration with Incyte, a Wilmington, Delaware-based biopharmaceutical company. Under the agreement, the companies will evaluate…

Daiichi Sankyo and Glycotope, a Berlin, Germany-headquartered biotechnology company, have signed an option agreement for future strategic collaboration and licensing to develop an antibody drug conjugate (ADC) by combining Daiichi…

Boehringer Ingelheim (BI) and Sarah Cannon Research Institute, the research arm of Nashville, Tennessee-based Sarah Cannon, a global cancer institute of the Hospital Corporation of America, have expanded their immuno-oncology…

Incyte Corporation, a Wilmington, Delaware-based biopharmaceutical company, and MacroGenics, a Rockville, Maryland-based clinical-stage biopharmaceutical company, have signed a license agreement worth up to $900 million for MacroGenics’ MGA012, an investigational…

Astellas Pharma’s Astellas Institute for Regenerative Medicine (AIRM) and Universal Cells,a Seattle-based biotechnology company, have signed an agreement to research, develop, and commercialize a cell therapy for an undisclosed indication.…

GlaxoSmithKline (GSK) and Plasticell, a biotechnology company using combinatorial cell-culture technologies for optimization of cell and gene-therapy manufacturing, have signed a pact to optimize induced pluripotent stem cells (iPSCs) differentiation…

AbbVie and Harpoon Therapeutics, a biotechnology company developing T-cell recruiting biologic therapies, have formed an immuno-oncology research collaboration. The goal of the collaboration is to incorporate Harpoon’s tri-specific T-cell activating…